Targeting KRAS mutations: orchestrating cancer evolution and ...
Nov 28, 2025 · In this review, we provide a brief overview of KRAS mutations in cancers and tumorigenesis, specifically focusing on currently approved therapies for targeting KRAS, …
What’s new in KRAS mutation research? - MD Anderson Cancer …
The most frequently mutated of these oncogenic driver genes, called KRAS, is associated with some of the most fatal cancer types: lung, pancreatic and colorectal cancers.
KRAS - Wikipedia
KRAS (Kirsten rat sarcoma virus oncogene homologue) is a gene that provides instructions for making a protein called K-Ras, a part of the RAS/MAPK pathway. The protein relays signals …
KRAS Mutations in Solid Tumors: Characteristics, Current …
Kristen rat sarcoma (KRAS) gene is one of the most common mutated oncogenes in solid tumors. Yet, KRAS inhibitors did not follow suit with the development of targeted therapy, for the …
An overview of KRAS G12D inhibitors: Expanding the
Frequencies and types of KRAS mutations KRAS mutations are widely distributed across human cancers, with approximately 11.6 % of all carcinomas and 25 % of tumors harboring KRAS …
Exploring KRAS: A precision approach in oncology - MSD
Jul 22, 2025 · KRAS is one of the most frequently mutated oncogenes found in cancer. In healthy cells, KRAS serves as an on-off switch that regulates cell growth. However, when the gene is …
The roles of KRAS in cancer metabolism, tumor ... - Springer
Jan 13, 2025 · In this review, we aim to summarize current knowledge on KRAS-related metabolic alterations in cancer cells and explore the prevalence and significance of KRAS mutation in …
Zoldonrasib Nets Breakthrough Therapy Designation in KRAS …
6 days ago · Zoldonrasib has received breakthrough therapy designation in pretreated KRAS G12D-mutated locally advanced or metastatic NSCLC.
Novel drug combination overcomes resistance in aggressive KRAS …
1 day ago · A research team at the Medical University of Vienna has discovered a new approach to treating a particularly frequent and difficult-to-treat form of lung cancer.
Zoldonrasib Earns FDA Breakthrough Therapy Designation in KRAS …
5 days ago · The FDA has granted breakthrough therapy designation to zoldonrasib (RMC-9805), an investigational RAS (ON) KRAS G12D inhibitor, as a treatment for adults with locally …